Skip to main content

Table 4 Success Rate by Use or Non-use of 3 Initial Monthly Injections (FAS Population)

From: Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration

  Overall
(n = 135)
With 3 initial monthly injections
(n = 71)
Without 3 initial monthly injections
(n = 64)
Success rate at 12 months,a
n (%) [95% CI]
90 (66.7)
[58.0–74.5]
49 (69.0)
[56.9–79.5]
41 (64.1)
[51.1–75.7]
BCVA, ETDRS letters
 Baseline 65.1 (13.7) 63.6 (12.3) 66.9 (15.1)
 Month 12 66.9 (15.0) 66.8 (12.1) 66.9 (17.8)
 Change in BCVA between initial visit and 12 months 1.7 (10.5) 3.3 (11.0) 0.0 (9.6)
P value 0.056 0.015 NS
CRT, μm
 Baseline 328.0 (100.9) 338.6 (114.6) 316.3 (82.5)
 Month 12 285.3 (84.3) 296.1 (88.0) 272.6 (78.6)
 Change in CRT between initial visit and 12 months −47.0 (104.1) −45.5 (106.0) −48.8 (102.6)
P value <  0.001 <  0.001 <  0.001
  1. All values are reported as mean (standard deviation) unless otherwise indicated
  2. P values are for the paired samples t test
  3. aPatients who gained ≥1 ETDRS letter (BCVA) and/or a reduction in CRT from baseline (prior to switch) to 12 months after the first intravitreal aflibercept injection
  4. BCVA Best–corrected visual acuity, CI Confidence interval, CRT Central retinal thickness, ETDRS Early Treatment Diabetic Retinopathy Study, FAS Full analysis set, NS Not significant
\